

# CARBOHYDRATES AND OTHER CELL ADHESION MOLECULES. CLINICAL AND DIAGNOSTIC IMPORTANCE

Magne BRYNE (\*), Jahn M. NESLAND (\*)

**SUMMARY : AND FUTURE DIRECTIONS.** Cell adhesion is of fundamental significance for fetal development, tissue organization, wound healing, inflammation and most pathological conditions. Increased understanding of cell adhesion at molecular level is necessary for development of a new potent treatments of various diseases. Alterations of expression of adhesion molecules will soon be of high diagnostic value for various diseases, including cancer.

Adhesion of cells to each other or to extracellular matrix is very important for various processes like embryonal development, maintenance of tissue architecture, angiogenesis, inflammation and cancer progression. Our knowledge about of cell adhesion has been very sparse, but the recent characterization of some families of cell adhesion molecules has significantly increased our understanding of these processes. Some of these families of adhesion molecules are cadherins, integrins, immunoglobulin superfamily, selectins and a few oligosaccharides. Three possibilities of cell adhesion are reported: 1) adhesion between similar molecules (homophilic binding), adhesion between different types of molecules (heterophilic binding) and cell-cell adhesion by means of a secreted linker molecule (1,2).

Expression of various cell adhesion molecules has proven to be of high diagnostic value for various diseases, including cancer. Promising animal studies have shown that blocking of cell adhesion can be a useful treatment of various inflammatory diseases and cancer.

In our department we work with carbohydrates as adhesion molecules and diagnostic markers and in the present review we will therefore mainly focus on the role of cell surface carbohydrates in biology, but also briefly describe other adhesion families.

## CADHERINS

Cadherins are proteins expressed on the surface most human cells and most of the cadherins are responsible for Ca<sup>2+</sup> dependent homophilic adhesion. They play crucial roles during embryonal development and hold neighbouring cells together in epithelial and nervous tissues. Significant alterations in cadherin synthesis are observed during progression of carcinomas and these findings have proven to be of prognostic value for various carcinomas (1,3,4)

## SELECTINS

Selectins (E-, P-, and L-selectin) are lectinlike carbohydrate binding proteins present on endothelial cells and some leucocytes (1,5). Endothelial selectins are activated by some cytokines and bind to carbohydrate containing counter-receptors on leucocytes. A small oligosaccharide structure, sialyl-Lewis X, is an important part of the counter-receptors for all selectins. Sialyl-Lewis X is chemically closely related to the ABH blood group antigens. The selectin-carbohydrate bindings occur in the initial phase ("rolling phase") of the trapping of leucocytes and possibly cancer cells into tissues. Several in-vivo studies show that blocking

of selectin binding can inhibit inflammation to a certain extent (6-9).

## IMMUNOGLOBULIN SUPERFAMILY

This group of glycoproteins have some biochemical similarities with antibodies and are involved in both homophilic and heterophilic cell-cell adhesions. One example is NCAM which bind nerve cells together in homophilic manner. Other molecules like ICAM, VCAM and MAdCAM are expressed on endothelial cells and are involved in homing of leucocytes in inflammation. They are counter-receptors for integrins (see below) on leucocytes and are important for successful adhesion and transmigration of leucocyte across the endothelial wall (1,5).

## INTEGRINS

This is a group of transmembrane proteins which are found on many cell types like leucocytes and epithelia. They have various adhesive functions. In inflammation, they bind to adhesion molecules of the immunoglobulin family on endothelial cells during the adhesion cascade necessary for recruitment of leucocytes into the tissues. Integrins have also important functions in the binding of cells to extracellular matrix proteins. Alterations in integrin expression are frequently observed in cancer and inflammatory disorders (2,5).

## THERAPEUTIC POTENTIAL OF BLOCKING ADHESIVE PROCESSES INVOLVING CARBOHYDRATES

### Adhesion of leucocytes or blood platelets


Leucocytes and blood platelets are necessary for various biological processes. However, they can also cause significant pathological damage. We will give some examples of studies showing that blocking of carbohydrate based adhesion can be clinically useful.

#### a) Reperfusion injury.

Reperfusion following ischemia often causes significant tissue injury and is a serious complication after myocardial infarction, organ transplantations, thermal skin injury and organ hypoperfusion (7). Reperfusion injury is associated with increased adhesion of neutrophilic granulocytes and activation of inflammatory cascades. It is mainly tissue destructive molecules from neutrophils that are responsible for the tissue injury. Several excellent animal studies have now shown that this injury can be significantly reduced by

\* Dept. of Pathol., The Norwegian Radiumhospital, Oslo, Norway

**FIG 1 : EXPRESSION OF THE ADHESION RELATED OLIGOSACCHARIDE SIALYL-LEWIS X IS STRONGLY ASSOCIATED WITH POOR PROGNOSIS OF PATIENTS HAVING ADVANCED PROSTATE CANCER. NEARLY ALL PATIENTS WITH SIALYL-LEWIS X EXPRESSION IN THE PRIMARY TUMOUR SHOWED A VERY POOR PROGNOSIS.**



blocking the adhesion of neutrophils to the endothelium by means of inhibiting carbohydrate-selectin interactions (7-10). For example, Buerke et al. (9) recently reported a 80% reduction of the myocardial necrosis with injection of the oligosaccharide sialyl-Lewis X after experimental ischemia compared with control animals. Thus, blocking of adhesion molecules may improve the prognosis for heart attack patients.

#### b) Transplantations.


Upregulation of adhesion molecules probably plays an importance during rejection reactions of transplanted organs (11,12). E-selectin is upregulated in various transplants, but no clinical studies of blocking of carbohydrate interactions during transplantation have so far been published. However, promising in-vivo results have been obtained by blocking other adhesion interactions (11). A major problem today is the lack of suitable organs and one possible strategy for successful xenotransplantation (transplantation across species) will be blocking of adhesive interactions (11).

#### c) Sepsis and septic shock.

Vascular injury and following hyperpermeability is one major cause to the serious complications from sepsis and septic shock (13). This endothelial injury is partly caused by adhesion of neutrophils and their local production of tissue destructive molecules. Activation of selectins and thus adhesion of neutrophils through their carbohydrate counterreceptors is thought to be important for this damage. Blocking of adhesion molecules is one potential new treatment of sepsis (14). Interestingly, it has recently been shown that E-selectin probably is of significant importance for the development of ARDS (acute respiratory distress syndrome). This is a very serious complication of sepsis and some other conditions (15).

#### d) Thrombosis and atherosclerosis.

Various adhesion molecules on platelets, leucocytes and endothelial cells are most likely crucial for the development of thrombi and atherosclerotic plaques (6,16-18). Platelets synthesize P-selectin, which bind to the oligosac-



*Fig 2 : Heterogenous expression of sialyl-Lewis X (indicating poor prognosis) in the primary tumour of a patient having advanced prostatic carcinoma. Benign epithelium did not express this structure.*

charide sialyl-Lewis X on leucocytes (16). In addition, E-selectin is reportedly upregulated on endothelial cell in relation to atheromatous plaques (19). These and many other findings suggest a potential role for carbohydrate dependant cell adhesion in these important diseases. The hope for therapy based on modification of cell adhesion in thrombosis and atherosclerosis is considerable, but further clinical research is needed before anti-adhesion therapy can improve the prognosis for these patients (18).

#### e) Rheumatoid arthritis and multiple sclerosis.

Rheumatoid arthritis and multiple sclerosis are both chronic diseases of unknown etiology. Recent research suggests that adhesion molecules are important for the homing of leucocytes to the tissue and for progression of the disease (20-22). Endothelial selectins are also upregulated in these chronic diseases. No clinical study using anti-carbohydrate therapy has been published yet. However, Ochi et al. (23) have recently demonstrated a 63% reduction of clinical symptoms in patients with rheumatoid arthritis by injecting an oligosaccharide (dimeric Lewis X) intradermally as a vaccine. This carbohydrate epitope is found on a rare myeloid cell which is upregulated in patients with rheumatoid arthritis.

## INFECTIONS

For many years it has been known that several microorganisms use carbohydrates for adhesion to tissues. *Helicobacter Pylori*, *Mycoplasma pneumonia*, HIV, Influenzae virus and E-coli well documented are examples (24-28). A few in-vivo studies show that infection (24) for example, urinary E-coli infection and diarrhoea caused by *Clostridium difficile*, can be inhibited by addition of various oligosaccharides (24,29). It is considered likely that anti adhesion therapy of some infections will be possible soon (24).

## CANCER

Probably all human cancers show significant alterations of glycoconjugates on the cell surface compared to their normal counterparts (30). The biological functions for sug-



ars on the cell surface of cancer cells are mainly unknown, but some are probably involved in adhesive interactions important for tumour progression (30-33). These carbohydrate changes can be used as diagnostic markers for various carcinomas (34). Upregulation or downregulation of some carbohydrate structures have prognostic value for example colo-rectal carcinomas (32), head and neck carcinomas (35) and prostate carcinomas (36) (Fig 1 and 2).

Carbohydrate based adhesion is most likely important during all steps in tumour progression (32,33). Many in-vitro studies have demonstrated that blocking of oligosaccharides can inhibit cancer cell adhesion to endothelium (5,31-33). Furthermore, some studies have shown that injection of carbohydrate blocking antibodies can inhibit tumour progression in mice (24,37). However, a lot of basic and clinical research is still needed before the dream of an anti-cancer "sugar-pill" is a reality.

In addition, recent in vitro studies suggest that carbohydrates have an important role during angiogenesis as adhesion molecules between endothelial cells (38). Thus, it is speculated that a novel anti-angiogenetic therapy based on blocking of carbohydrate interactions will be clinically useful as a cancer treatment.

## DEVELOPMENT OF CARBOHYDRATE BLOCKING PHARMACEUTICALS

The potential high clinical importance of carbohydrate adhesion has stimulated many pharmaceutical companies to work hard for creating clinically useful therapeutics (33,39,40). Carbohydrate based adhesion to selectins on endothelium may in theory be blocked by a) antibodies, b) free oligosaccharides, c) free selectinlike peptides, d) "glycomimetics" (molecules mimicking oligosaccharide), and e) blocking biosynthesis of adhesion molecules or cytokines important for activation of adhesion molecules. Several problems are still to be solved; free oligosaccharides are expensive and have a short half life, the relevant monoclonal antibodies are rarely human and have thus a short half life and can only be administered intravenously, and several side effects are to be expected because some of the relevant molecules are present on some normal cells. In addition, blocking of biosynthesis of carbohydrates by means of glycosylation inhibitors or gene-therapy is possible, but will also most likely have side effects depending partly on how selective the blocking can be done. Some promising results from the pharmaceutical companies have, however, been recently published (39,40). For acuted and life threatening conditions like severe infections, septic chock, ARDS and reperfusion injury, the potential side effects and cost of the treatment are not necessarily important. For more chronic conditions, like rheumatoid arthritis and cancer, the side effects will probably be a greater problem.

## Acknowledgements

We thank The Norwegian Cancer Society for support

## REFERENCES

1. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J.D. Molecular biology of the cell. New York: Garland Publishing, 1994.
2. Hynes, R.O. The impact of molecular biology on models for cells adhesion. *BiolEssays*, 16: 663-669, 1994.
3. Otto, T., Rembrink, K., Goepel, M., Meyer Schickerath, M., and Rubben,

- H. E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. *Urol. Res.*, 21: 356-362, 1993.
4. Mattijssen, V., Peters, H.M., Schalkwick, L., Manni, J.J., van't Hof Groenboer, B., de Mulder, P.H., and ruiter, D.J. E-cadherin expression in head and neck squamous-cell carcinoma is associated with clinical outcome. *Int. J. Cancer*, 55: 580-585, 1993.
5. Springer, T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell*, 76: 301-314, 1994.
6. Adams, D.H. and Shaw, S. Leucocyte-endothelial interactions and regulation of leucocyte migration. *lancet*, 343: 831-836, 1994.
7. Lefer, A.M., Weyrich, A.S., and Buerke, M. Role of selectins, a new family of adhesion molecules, in ischaemia-reperfusion injury. *Cardiovasc. Res.*, 28: 289-294, 1994.
8. Mulligan, M.S., Lowe, J.B., Larsen, R.D., Paulson, J., Zheng, Z.L., DeFrees, S., Maemura, K., Fukuda, M., and Ward, P.A. Protective effects of sialylated oligosaccharides in immune complex-induced acute lung injury. *J. Exp. Med.*, 178: 623-631, 1993.
9. Buerke, M., Weyrich, A.S., Zheng, Z., Gaeta, F.C., Forrest, M.J., and Lefer, A.M. Sialyl Lewisx-containing oligosaccharide attenuates myocardial reperfusion injury in cats. *J. Clin. Invest.*, 93: 1140-1148, 1994.
10. Ley, K. Molecular mechanisms of leucocyte rolling and adhesion to microvascular endothelium. *Eur. Heart J.*, 14 Suppl I: 68-73, 1993.
11. Heemann, U.W., Tullius, S.G., Azuma, H., Kupiec Weglinsky, J., and Tilney, N.L. Adhesion molecules and transplantation [see comments]. *Ann. Surg.*, 219: 4-12, 1994.
12. Platt, J.L. Connection between cell adhesion and transplantations [editorial; comment]. *Ann. Surg.*, 219: 1-3, 1994.
13. Barron R.L. Pathophysiology of septic shock and implications for therapy. *Clin. Pharm.*, 12: 829-845, 1993.
14. Mercier, J.C. New treatments for sepsis. *Crit. Care Med.*, 21: S310-S314, 1993.
15. Donnelly, S.C., Haslett, C., Dransfield, I., Robertson, C.E., Carter, D.C., Ross, J.A., Grant, I.S., and Tedder, T.F. Role of selectins in development of adult respiratory distress syndrome. *Lancet*, 344: 215-219, 1994.
16. Palabrica, T., Lobb, R., Furie, B.C., Aronovitz, M., Benjamin, C., Hsu, Y.M., Sajer, S.A., and Furie, B., leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. *Nature*, 359:848-851, 1992.
17. Nash G.B. Adhesion between neutrophils and platelets: A modulator of thrombotic and inflammatory events. *Thromb. Res.*, 74 Suppl. 1: S3-S11, 1994.
18. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature*, 362: 801-809, 1993.
19. Davies, M.J., Gordon, J.L., Gearing, A.J., Pigott, R., Woolf, N., Katz, D., and Kyriakopoulos, a. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. *J. Pathol.*, 171: 223-229, 1993.
20. Moreland, L.W., Heck, L.W., Jr., Sullivan W., Pratt P.W., and Koopman W.J. New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm. *Am. J. Med. Sci.*, 305: 40-51, 1993.
21. Hintzen R.Q., Polman, C.H., Lucas, C.J., and van Lier, R.A. Multiple sclerosis: immunological findings and possible implications for therapy. *J. Neuroimmunol.*, 39:1-10, 1992.
22. Postigo, A.A., Garcia Vicuna, R., Laffon, a., and Sanchez Madrid, F. The role of adhesion molecules in the pathogenesis of rheumatoid arthritis. *Autoimmunity*, 16: 69-76, 1993.
23. Ochi, T., Hakomori, S., Fujimoto, M., Okamura, M., Owaki, H., Wakitani, S., Shimaoka, Y., Hayashida, K., Tomita, T., Kawamura, S., et al. Therapeutic effect of intradermal injections with difucosyl lactosamine (dimeric Lex) on patients with rheumatoid arthritis. *J. Rheumatol.*, 20: 2038-2045, 1993.
24. Sharon, N. and Lis, H. Carbohydrates in cell recognition. *Sci. Am.*, 268: 82-89, 1993.
25. Boren, T., Falk, P., Roth, K.A., Larson, G., and normark, S. Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens [see comments]. *Science*, 262: 1892-1895, 1993.
26. Feizi, T. Carbohydrates and the pathogenesis of *Mycoplasma pneumoniae* infection and AIDS-some observations and speculations. *Clin. Infect. Dis.*, 17 Suppl 1: S63-S65, 1993.
27. Sorensen, A.M., Nielsen, C., Arendrup, M., Clausen H., Nielsen, J.O., Osinaga, E., Roseto, A., and Hansen, J.E. Neutralization epitopes on HIV pseudotyped with HTLV-I: conservation of carbohydrate epitopes. *J. Acquir. Immune. Defic. Syndr.*, 7: 116-123, 1994.
28. Couceiro, J.N., Paulson, J.C., and baum, L.G. Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. *Virus Res.*, 29: 155-165, 1993.
29. Heerze, L.D., Kelm, M.A., Talbot, J.A., and Armstrong, G.D. Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis. *J. Infect. Dis.*, 169: 1291-1296, 1994.

30. Hakomori, S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. *Adv. Cancer Res.*, 52: 257-331, 1989.
31. Sawada, R., Lowe J.B., and Fukuda, M. E-selectin-dependent adhesion efficiency of colonic carcinoma cells is increased by genetic manipulation of their cell surface lysosomal membrane glycoprotein-1 expression levels. *J. Biol. Chem.*, 268: 12675-12681, 1993.
32. Irimura, T., Nakamori, S., Matsushita, Y., Taniuchi, Y., Todoroki, N., Tsuji, T., Izumi, Y., Kawamura, Y., Hoff, S.D., Cleary, K.R. et al. Colorectal cancer metastasis determined by carbohydrate-mediated cell adhesion: role of sialyl-LeX antigens. *Semin. Cancer Biol.*, 4: 319-324, 1994.
33. Varki, A. Selectin ligands. *Proc. Natl. Acad. Sci. USA*, 91: 7390-7397, 1994.
34. Muramatsu, T. Carbohydrate signals in metastasis and prognosis of human carcinomas. *Glycobiology*, 3: 291-296, 1993.
35. Byrne, M., Thrane, P.S., and Dabelsteen, E. Loss of expression of blood group antigen H is associated with cellular invasion and spread of oral squamous cell carcinomas. *Cancer*, 67: 613-618, 1991.
36. Jorgensen, T., Berner, A., Kallhus, O., Tveter, K.J., Danielsen, H., and Bryne, M. Up-regulation of the oligosaccharide sialyl-Lewis X. A new prognostic parameter in metastatic prostate cancer. *Cancer Res.*, In press: 1995.
37. Young, W.W. and Hakomori, S. Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo. *Science*, 211: 487-489, 1981.
38. Nguyen, M., Strubel, N.A., and Bischoff, J. A role for sialyl Lewis X/A glycoconjugates in capillary morphogenesis. *Nature*, 365: 267-269, 1993.
39. Narasinga Rao, B.N., Anderson, M.B., Musser, J.H., Gilbert, J.H., Schaefer, M.E., Foxall, C., and Brandley, B.K. Sialyl Lewis X mimics derived from a pharmacophore search are selectin inhibitors with anti-inflammatory activity. *J. Biol. Chem.*, 269: 19663-19666, 1994.
40. Parekh, R.B. and Edge, C.J. Selectins-Glycoprotein targets for therapeutic intervention in inflammation. *Trends Biotechnol.*, 12: 339-345, 1994.